胃癌藥物市場：依治療方法、應用、通路和地區分類

Stomach Cancer Drugs Market, By Therapy Type, By Application, By Distribution Channel, By Geography

出版日期: 2026年01月29日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，胃癌治療市場規模將達到 56 億美元，到 2033 年將達到 91 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 7.2%。

報告內容		報告詳情
基準年：	2025	2026年市場規模：	56億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
預測期（2026-2033年）複合年成長率：	7.20%	預計2033年價值：	91億美元

根據世界癌症研究基金會（WCRF）2018年的報告，胃癌是全球第五大常見癌症，不分性別。胃癌的病因多種多樣，包括不健康的飲食、吸煙、肥胖、飲酒以及幽門螺旋桿菌病菌感染。英國癌症研究中心2016年的資料顯示，英國每年新增的胃癌病例中，有三分之一與幽門螺旋桿菌感染有關。胃癌篩檢可以確定病菌感染的分期，並據此指導治療。標靶藥物治療常用於治療胃癌，因為它能夠針對快速分裂的細胞，且副作用較少。目前，針對HER2標靶藥物正在研發中，用於治療進行性胃癌。例如，Pertuzumab、曲妥珠單抗和化療的聯合治療目前正在進行治療轉移性胃食道交界處癌或胃癌的III期臨床試驗。

市場動態

全球胃癌發生率的不斷上升預計將推動胃癌治療市場的擴張。例如，根據世界癌症研究基金會（WCRF）2018年的數據，當年約有100萬例胃癌確診病例。此外，人口老化是患胃癌的高風險因素，男性尤其容易罹患此病。例如，根據美國癌症協會（ACS）2014年的報告，胃癌患者的平均確診年齡為68歲。報告也指出，每年確診的胃癌患者中，十分之六為65歲及以上的老年人，使得胃癌成為男性第四大常見癌症。

然而，胃癌藥物市場面臨的一大挑戰是治療費用高昂，這在許多國家對中低收入家庭來說難以負擔。根據2017年發表在權威期刊《Oncotarget》的數據，胃癌藥物（包括曲妥珠單抗）的費用四周可達8,000美元，一年可達9,6,000美元。

本次調查的主要特點

本報告以 2017 年為基準年，對胃癌藥物市場、市場規模以及預測期（2018-2026 年）的複合年成長率（%）進行了詳細分析。
該報告重點介紹了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
該研究根據以下參數對全球胃癌治療市場的主要企業進行了分析：公司概況、財務表現、產品系列、地理分佈、分銷策略、關鍵發展和策略。
主要企業包括輝瑞公司、禮來公司、葛蘭素史克公司、庫尼爾製藥株式會社、第一三共株式會社、默克集團、阿斯特捷利康公司、大塚控股株式會社、賽諾菲公司、羅氏公司、小野藥品工業株式會社、百時美恆瑞寶公司、江蘇蘇蘇公司。此外，還有吉利德科學公司、新基公司、大鵬藥品工業株式會社、波士頓生物醫學公司和默克公司。
本報告的研究結果將使負責人和經營團隊能夠就即將推出的產品、政府政策、技術創新、市場擴張和行銷策略做出明智的決策。
這份全球胃癌藥物市場報告的目標受眾是業內各相關人員，包括投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

Pfizer Inc.
Eli Lilly and Company
GlaxoSmithKline Plc.
Kuhnil Pharmaceutical Co. Ltd.
Daiichi Sankyo Co. Ltd.
Merck KGaA
AstraZeneca Plc.
Otsuka Holdings Co. Ltd.
Sanofi SA
F. Hoffmann-La Roche Ltd.
Ono Pharmaceutical Co. Ltd.
Bristol-Myers Squibb（BMS）
Jiangsu HengRui Medicine Co. Ltd.
Gilead Science Inc.
Celgene Corporation
Taiho Pharmaceutical
Boston Biomedical Inc.
Merck &Co.

第9章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第10章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2667

Stomach Cancer Drugs Market is estimated to be valued at USD 5,600 Mn in 2026 and is expected to reach USD 9,100 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 5,600 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.20%	2033 Value Projection:	USD 9,100 Mn

Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the World Cancer Research Fund (WCRF) in 2018. There are many factors which cause stomach cancer such as unhealthy diet, smoking, obesity, alcohol, and Helicobacter pylori infection. According to the Cancer Research U.K. data of 2016, one out of three stomach cancer cases is related to Helicobacter pylori infection in the U.K. annually. Stomach cancer tests identify the stage of the cancer and the patient is treated accordingly. Targeted drug therapies are frequently used to treat stomach cancer as these drugs target the rapidly dividing cells and have less side effects. Drugs that target HER2 are under developmental studies to treat advanced stomach cancer. For instance, pertuzumab in combination with trastuzumab and chemotherapy is under phase 3 clinical trials to treat metastatic gastroesophageal junction or gastric cancer.

Market Dynamics

Increasing prevalence of stomach cancer worldwide is expected to boost the stomach cancer drugs market size. For instance, according to WCRF data of 2018, around one million cases of stomach cancer were diagnosed in 2018. Furthermore, increasing geriatric population is at a high risk of developing stomach cancer and men are more vulnerable to developing stomach cancer. For instance, according to the American Cancer Society (ACS) report in 2014, the average age of people diagnosed with stomach cancer is 68. As per the same source, six out of ten people diagnosed with stomach cancer annually are 65 or older, and stomach cancer is the fourth most common cancer in men.

However, the major challenge in the stomach cancer drugs market are the high expenses related to treatment of stomach cancer, which are not affordable to the middle to low income families in most countries. According to a data published in Oncotarget (impact journal) in 2017, the cost of stomach cancer drugs (considering Trastuzumab) can reach up to US$ 8,000 for four weeks and annually it can reach up to US$ 96,000.

Key features of the study

This report provides in-depth analysis of the stomach cancer drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global stomach cancer drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, government initiatives, technological up-gradation, market expansion, and marketing tactics
The global stomach cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for stomach cancer drugs market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

Therapy Type Insights (Revenue, USD Mn, 2026 - 2033)
- Kinase Inhibitors
- Nucleoside Metabolic Inhibitors
- Anthracyclines
- VEGF Antibodies
- HER2 Receptor Antagonists
- Car T Cell Therapy Trastuzumab
- Trastuzumab
Application Insights (Revenue, USD Mn, 2026 - 2033)
- Adenocarcinomas
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Endoscopic Surgery
- Surgical Suite
- Dental Surgery
- Others
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
Key Players Insights
- Pfizer Inc.
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- Kuhnil Pharmaceutical Co. Ltd.
- Daiichi Sankyo Co. Ltd.
- Merck KGaA
- AstraZeneca Plc.
- Otsuka Holdings Co. Ltd.
- Sanofi S.A.
- F. Hoffmann-La Roche Ltd.
- Ono Pharmaceutical Co. Ltd.
- Bristol-Myers Squibb (BMS)
- Jiangsu HengRui Medicine Co. Ltd.
- Gilead Science Inc.
- Celgene Corporation
- Taiho Pharmaceutical
- Boston Biomedical Inc.
- Merck & Co.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Global Stomach Cancer Drugs Market, By Therapy Type
- Global Stomach Cancer Drugs Market, By Application
- Global Stomach Cancer Drugs Market, By Distribution Channel
- Global Stomach Cancer Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Stomach Cancer Drugs Market, By Therapy Type, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Nucleoside Metabolic Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
VEGF Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
HER2 Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Car T Cell Therapy Trastuzumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Trastuzumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Stomach Cancer Drugs Market, By Application, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adenocarcinomas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Gastrointestinal Stromal Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Carcinoid Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Stomach Cancer Drugs Market, By Distribution Channel, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

7. Global Stomach Cancer Drugs Market, By Region, 2020 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Value (USD Mn)
- Market Size and Forecast, By Therapy Type, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kuhnil Pharmaceutical Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Daiichi Sankyo Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Holdings Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ono Pharmaceutical Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb (BMS)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Jiangsu HengRui Medicine Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Science Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Taiho Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boston Biomedical Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies